Molecular Toxicology, Institute of Toxicology, Merck KGaA, 64271 Darmstadt, Germany
Received November 5, 2003; accepted January 2, 2004
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key Words: PPAR; HepG2; FAO; primary hepatocytes; fibrates; Wy 14643.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
These species differences in PPAR function have been the focus of several research papers (reviewed in Cattley et al., 1998
). The functions of rat and human PPAR
are similar and homology of the DNA binding domain and ligand binding domain is high (Goettlicher et al., 1992
; Mukherjee et al., 1994
; Sher et al., 1993
); however, human hepatocytes display only weak induction of marker enzyme activity like acyl CoA oxidase (ACOX). Several determining factors for the different activities of PPAR
in rat vs. human hepatocytes have been identified. One factor might be due to the lower expression levels of PPAR
in human liver compared to rats (Tugwood et al., 1996
) and a second factor might be the existence of an inactive PPAR
splice variant in human liver samples (Palmer et al., 1998
). Another factor has been shown to be the responsiveness of PPAR
regulated genes that is defined by PPAR response elements (PPRE) located within the promoter region of target genes. Both human and rat ACOX gene promoter contain the consensus PPRE half site TGACCT and a second nonconsensus half-site (Tugwood et al., 1992
; Varanasi et al., 1996
, 1998
). Comparison of the rat and human promoter sequences revealed that the human ACOX PPRE did not mediate PPAR
activity; however, human PPAR
displayed activity on the rat ACOX promoter (Hasmall et al., 2000
; Lambe et al., 1999
) and was able to induce endogenous genes involved in lipid metabolism (Lawrence et al., 2001
).
Our aim was to determine whether PPAR and the PPRE sequences are sufficient to account for these species differences. We, therefore, analyzed the contribution of PPAR
, PPRE and in particular how and to what extent the cellular environment may determine PPAR
-mediated responses in rat and human hepatocytes. First, marker enzyme inductions in rat primary hepatocytes, the rat hepatoma FAO, and the human hepatoma HepG2 cell line were investigated. In transient transfection studies we then examined whether human or rat PPAR
exert activity on a rat or human PPRE derived from the ACOX promoter in rat and human hepatocytes. Subsequently, we measured expression of endogenous peroxisomal marker genes as well as of human PPAR
responsive genes in rat and human primary hepatocytes in the presence or absence of transfected rat or human PPAR
. This comprehensive analysis revealed that all parameters investigated determined the species-specificity of peroxisome proliferation and that human hepatocytes limited PPAR
activity.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cell culture.
HepG2 and FAO cells were cultured in Dulbecco's modified Eagle medium (DMEM)/F12 supplemented with 10% FBS and 5% FBS, respectively, 1 mM sodium pyruvate and antibiotics. Cells were cultured at 37°C/5% CO2 in air in a humidified atmosphere.
Isolation of primary hepatocytes from rat liver.
Primary rat hepatocytes were prepared freshly from male Wistar rats (200250 g) by the in situ perfusion procedure (Seglen, 1973, 1976
). Livers were perfused with 0.5 mg/ml collagenase, the liver capsule removed, and the released hepatocytes filtered through a 250 µm mesh followed by a second filtration step using a 100 µm mesh nitex membrane. The filtered hepatocytes were resuspended in phenol-red free DMEM/F12 supplemented with 10% DCC/FBS and 5 µg/ml insulin. The cell number and viability of the suspension was assessed by trypan blue exclusion. Fifty µl trypan blue was mixed with 50 µl cell suspension and the number of viable cells (cells that were not stained with trypan blue) were determined in a hemacytometer. Primary cell cultures that had a viability of more than 80% were used for the experiments. For better attachment and viability of primary hepatocytes, tissue culture plates were coated with 6 µg/cm2 collagen I. For attachment, rat hepatocytes were cultured at 37°C/5% CO2 in air in a humidified atmosphere for at least 3 h prior to the experiments.
Thawing of cryopreserved human hepatocytes.
Cryopreserved human hepatocytes were thawed according to the procedure provided by the manufacturer (In Vitro Technologies, Baltimore, MD). Briefly, two vials of cryopreserved human hepatocytes were rapidly thawed and poured into 40 ml of phenol-red free DMEM/F12 supplemented with 10% DCC/FBS and centrifuged at 60 x g for 5 min. The cell pellet was resuspended in 5 ml phenol-red free DMEM/F12 supplemented with 10% DCC/FBS and 5 µg/ml insulin. The cell number and viability was assessed as described for rat hepatocytes and primary cell cultures that had a viability of more than 80% were used for the experiments. Primary hepatocytes were seeded on collagen-coated plates. For attachment, human hepatocytes were cultured at 37°C/5% CO2 in air in a humidified atmosphere for at least 3 h prior to the experiments.
Cytotoxicity assay.
For assessing cytotoxicity and cell proliferation induced by the test compounds the WST-1 kit was used according to the protocol provided by the manufacturer (Roche, Mannheim, Germany). This test measures the enzymatic formation of formazan. The formazan formation correlates with cellular enzyme activity and cell number. Therefore, a decrease in formazan formation and hence absorption indicates cytotoxicity. FAO and HepG2 cells were seeded at a density of 0.5 x 105 cells/cm2 while 2 x 105 primary cells/cm2 were seeded in 96-well plates. IC50 values (compound concentration yielding 50% inhibition of formazan formation) were derived by nonlinear curve-fitting of dose-response curves using Origin software (Microcal Software, Northhampton, MA) and are given as mean ± SD of at least three independent experiments.
Protein extraction and determination for enzyme activity assays.
Fifteen hours prior to treatment, cells were seeded in culture medium. FAO and HepG2 cells were seeded at a density of 0.2 x 105 cells/cm2 while 2 x 105 primary cells/cm2 were seeded in tissue culture plates. Then, test compounds were added (vehicle was dimethyl sulfoxide [DMSO] at 0.1% volume per volume (v/v) final concentration). The medium was changed every 24 h during treatment. The cells were harvested in ice cold PBS buffer and lysed in 0.1 % (v/v) Triton X-100 in PBS buffer. Protein concentrations were determined according to Bradford (1976) with bovine serum albumin as standard.
Acyl-CoA oxidase (ACOX) activity.
Palmitoyl-CoA oxidase activity was assayed by determining the production of hydrogen peroxide using a modified photometric detection method (Small et al., 1985). The reaction medium contained 11 mM phosphate buffer and 40 mM aminotriazol buffer at pH 7.4, 0.8 mg horseradish peroxidase IV-A, 0.05 mM leuco-dichlorodihydro-fluoresceine diacetate and cell homogenate containing 50 to 200 µg of protein in 300 µl. The reaction was started by the addition of 10 µl of 3 mM palmitoyl-CoA lithium salt solution in 11 mM phosphate buffer pH 7.4. The enzyme kinetic was measured for 10 min at 490 nm.
Catalase activity.
The catalase activity was determined by a photometric method (Hübl and Breitschneider, 1964). The assay was performed at 4°C. The reaction mixture (200 µl) contained 20 mM imidazole-HCl buffer pH 7, 0.1% weight per volume (w/v) delipidated bovine serum albumin, and 1.5 mM hydrogen peroxide. The reaction was started by the addition of the cell homogenate (540 µg protein/ml) and stopped with 100 µl of 2 M sulfuric acid containing 0.125 % (w/v) titanium oxysulfate. The remaining hydrogen peroxide was measured at 412 nm by the absorption of peroxytitanium sulfate.
Carnitine-acyltransferase activity.
Carnitine-acyltransferase (CAT) activity was determined according to (Bieber and Markwell, 1981) with slight modifications. The reaction volume was 200 µl containing 125 mM Tris-HCl buffer pH 8.0, 2.5 mM ethylenediaminetetraacetic acid, 0.5 mM dithionitrobenbenzoeacid (DTNB), 0.2 mM acetyl-CoA, and 20500 µg protein. The reaction was started by addition of 5 mM L-carnitine. The DTNB complex was measured for 10 min at 412 nm.
Generation and characteristics of expression and reporter plasmids.
The mammalian expression plasmids for human and rat PPAR (pSG5-hPPAR
and pSG5-rPPAR
, respectively) were kindly provided by W. Wahli (IBA, Geneva, Switzerland). The mammalian expression plasmid for human RXR
(pcDNA4-hRXR
) was generated using standard cloning procedures (Ausubel et al., 1998
). The full-length cDNA of human RXR
(GenBank accession number NM_002957; nucleotide positions 551559) was cloned into pcDNA4-HisMAX (Invitrogen, Karlsruhe, Germany) using the TOPO TA cloning kit (Invitrogen, Karlsruhe, Germany) and total RNA isolated from human liver samples. The correct sequence of the cDNA was verified by sequencing. Firefly luciferase reporter plasmids were generated by placing three copies of the rat (Tugwood et al., 1992
) or human (Varanasi et al., 1996
, 1998
) PPAR
response element derived from the ACOX promoter (rat ACOX PPRE: TGACCTTTGTCCT and human ACOX PPRE: AGGTCAGCTGTCA) in the multiple cloning site of the pGL3-SV40 reporter plasmid (Promega, Mannheim, Germany) and named pGL3-SV40-3xrPPRE and pGL3-SV40-3xhPPRE, respectively. The luciferase reporter containing the full-length rat ACOX promoter (pGL3-rACOX) was kindly provided by J. Tugwood (AstraZenca, UK; (Tugwood et al., 1992
)).
Transient transfection and transactivation assay.
HepG2 and FAO cells were seeded on 24-well plates 15 h prior to transfection in phenol-red free DMEM/F12 supplemented with 10 and 5% DCC/FBS, respectively. 0.2 x 106 viable primary hepatocytes were dispensed per well in collagen-coated 24-well plates in phenol-red free DMEM/F12 supplemented with 10% DCC/FBS and 5 µg/ml insulin as described above. The plasmids were transfected in phenol-red free DMEM/F12 supplemented with 5% DCC/FBS using Fugene 6 (Roche, Mannheim, Germany) according to the protocol provided by the manufacturer. Each well received 0.1 µg empty pSG5, pSG5-hPPAR or pSG5-rPPAR
, 0.1 µg of pcDNA4-hRXR
, 0.5 µg of firefly luciferase reporter and 0.01 µg pRL-CMV (Renilla luciferase for normalization; Promega, Mannheim, Germany). After transfection, cells were treated with test compounds (final concentration of vehicle DMSO 0.5 % v/v) for 22 h in medium supplemented with 10 % DCC/FBS as described above. Luciferase assays were performed using the Dual-Luciferase Reporter Assay System (Promega, Mannheim, Germany) according to the protocol provided by the manufacturer. Each value was normalized for cell number and transfection efficiency to the luciferase control (pRL-CMV) and each data point obtained represents the average of duplicate determinations. All experiments were repeated at least three times. EC50 values (ligand concentration yielding half-maximal activation) were derived by nonlinear curve-fitting of transactivation curves using Origin software (Microcal Software, Northhampton, MA) and are given as mean ± SD of at least three independent experiments. Control transfections were performed using 0.5 µg empty pGL3-basic (Promega, Mannheim, Germany) instead of reporter vector per well. Transfection efficiencies were highest in HepG2 cells (average of four tests: 20,000 light units of pRL-CMV per well) and were in FAO approximately 25 % compared to HepG2 (average of four tests: 5000 light units of pRL-CMV per well). Primary rat hepatocytes displayed transfection efficiencies of 3000 light units of pRL-CMV per well (average of four tests), and primary human hepatocytes displayed transfection efficiencies of 2000 light units of pRL-CMV per well (average of three tests).
RNA extraction and isolation.
The RNA was isolated according to the instructions given by the manufacturer (QIAGEN RNeasy® Mini Kit, Hilden, Germany) using additionally a QIAshredder spin column (QIAGEN, Hilden, Germany) and DNA digestion (QIAGEN DNase Kit, Hilden, Germany).
Real-time quantitative PCR.
The purified RNA was subjected to reverse transcription using random hexamers and TaqMan® reverse transcription reagents (Applied Biosystems, Weiterstadt, Germany) according to the protocol provided by the manufacturer. The primer and probes used for the real time PCR assay were designed using the PrimerExpress software (Applied Biosystems, Weiterstadt, Germany) and oligonucleotides were synthesized by Applied Biosystems (Weiterstadt, Germany). Target genes with sequences of primer and probes used are listed in Table 1. The probes were all labeled with the fluorescent dyes FAM (6-carboxy-fluorescein) and TAMRA (6-carboxy-tetramethyl-rhodamin) at the 5'- and 3'-end, respectively (Applied Biosystems, Weiterstadt, Germany). Real-time PCR was performed on an Applied Biosystems ABI Prism 7000 Sequence Detection System. The primer concentration was optimized prior to use with a fixed probe concentration of 200 nM in a TaqMan® Universal PCR buffer (Applied Biosystems, Weiterstadt, Germany) in 25 µl reaction volume per well. All samples were run in triplicates and a standard curve from 2.5 to 20 ng cDNA was generated for each experiment. Ten ng of sample cDNA was used and normalized to 18S ribosomal RNA (rRNA) control (for human and rat 18S rRNA pre-developed TaqMan assay reagents [PDAR] were used; Applied Biosystems, Weiterstadt, Germany). Forty-one cycles were run with the following parameters: 2 min at 50°C, 10 min at 95°C and for each cycle 15 s at 95°C for denaturation and 1 min at 60°C for transcription. Two different negative controls were performed, one omitting the reverse transcription step and one omitting target RNA. Assays were evaluated only when the negative controls did not show any amplification products.
|
|
|
|
|
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
PPAR, PPRE, and the Cellular Environment Determine the Different Transactivation in Rat Compared to Human Hepatocytes
We further examined whether the species-specific activity of peroxisome proliferators were due to rat or human PPAR or the promoter sequences. For this purpose, FAO, HepG2, as well as rat and human primary hepatocytes were transfected with either rat or human PPAR
expression vectors. As reporter genes we used either a rat (Tugwood et al., 1992
) or human (Varanasi et al., 1996
, 1998
) ACOX PPRE or the rat full-length ACOX promoter (Tugwood et al., 1992
). Control transfections were performed with a reporter vector lacking PPRE sequences that did not show any induced activity (data not shown). Wy 14,643 as well as ciprofibrate induced a dose-dependent increase of full-length rat ACOX and rat ACOX PPRE reporter gene activity in rat primary hepatocytes and rat FAO cells, but not in primary human hepatocytes or HepG2 cells (data not shown). The potencies (EC50) of Wy 14,643 and ciprofibrate to induce PPAR
were comparable in rat hepatocytes and FAO on both rat ACOX PPRE (3xPPRE) and the full-length ACOX promoter (Table 3).
|
|
Since the effects observed in FAO and HepG2 cells could be due to the transformed cell type and may not reflect the physiology in hepatocytes, we performed the same experiments in primary rat and human hepatocytes (Fig. 4). The rat primary hepatocytes facilitated marked peroxisome proliferator induced activity of rat PPAR on rat ACOX PPRE or the full-length ACOX promoter only (Fig. 4A). In contrast to the results obtained in FAO cells (Fig. 3A), induction of the full-length ACOX promoter was not increased by transfection of rat or human PPAR
into rat primary hepatocytes (Fig. 4A), which is likely due to high level of endogenous PPAR
expression (see below) and/or the high basal activity of transfected rat PPAR
in primary rat hepatocytes (Fig. 2). In agreement with the results obtained in HepG2 cells (Fig. 3B), we did not observe any distinct PPAR
-mediated activity in human hepatocytes (Fig. 4B). Surprisingly, transfected rat PPAR
did not increase the induction of rat ACOX PPRE or ACOX promoter by Wy 14,643 or ciprofibrate in human hepatocytes (Fig. 4B), although the transfection efficiencies of rat and human PPAR
were comparable for primary rat and human hepatocytes (see Materials and Methods section).
PPAR mRNA Is Highly Abundant in Rat But Not in Human Hepatocytes
Since rat but not human hepatocytes showed PPAR-mediated activity (Figs. 2 and 4), we analyzed the basal mRNA expression levels of endogenous PPAR
in the rat and human cell lines used (Table 4). As expected, the basal expression level of endogenous PPAR
in rat FAO cells was more than 4-fold higher compared to human HepG2 cells. Rat primary hepatocytes showed the highest basal expression levels of PPAR
whereas HepG2 and human primary hepatocytes had similar, low basal expression levels of human PPAR
(Table 4).
|
|
It is well established that rat hepatocytes respond to peroxisome proliferators by induction of ACOX whereas human hepatocytes remain refractory (Lawrence et al., 2001). We have therefore extended our study and investigated the effects of both endogenous PPAR
and transfected rat or human PPAR
on the expression of ACOX and other rat and human PPAR
responsive genes, i.e., 3-hydroxy-3-methylglutaryl-CoA synthase (HMGCS), carnitine palmitoyl transferase-1A (CPT1A), and apolipoprotein CIII (apo CIII; Brandt et al., 1998
; Hsu et al., 2001
; Lawrence et al., 2001
; Rodriguez et al., 1994
; Staels et al., 1995
). Based on the time-course experiments of ACOX expression (Figs. 5 and 6), we treated FAO, HepG2, primary rat and human hepatocytes for 24 h with 100 µM Wy 14,643 and analyzed PPAR
target gene expression (Figs. 79). Transfection of rat and human hepatocytes as well as hepatoma cells with human or rat PPAR
cDNA yielded a distinct increase of human or rat PPAR
mRNA expression, respectively (Figs. 7 and 8). Furthermore, transfected rat PPAR
increased basal ACOX expression levels in FAO (Fig. 7A) but not in primary rat hepatocytes (Fig. 8A), which is likely due to the higher endogenous PPAR
expression in primary rat hepatocytes compared to FAO cells (Table 4). Wy 14,643 distinctively induced ACOX gene expression in mock and rat PPAR
transfected FAO as well as in rat hepatocytes (Figs. 7A and 8A). Increased human PPAR
mRNA expressionup to similar levels as observed for rat PPAR
in rat hepatocytes (Figs. 7 and 8)as well as overexpression of rat PPAR
mRNA did not distinctively increase the susceptibility to ACOX induction by Wy 14,643 in HepG2 or human hepatocytes (Figs. 7B and 8B).
|
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
To this end, we first analyzed induction of the marker enzymes ACOX and CAT as well as catalase in rat and human hepatocytes. Confirming earlier reports (Duclos et al., 1997; Perrone et al., 1998
; Stangl et al., 1995
), fibrates induced strongly ACOX and CAT but to a lesser extent catalase in rat hepatocytes whereas human HepG2 cells were refractory. To investigate whether the observed distinct enzyme induction is due to differences in the PPRE sequence of the ACOX gene (Lambe et al., 1999
), the PPAR
(Lawrence et al., 2001
), or the cellular environment of rat vs. human, we analyzed the activity of either rat or human PPAR
on a rat or human ACOX-derived PPRE (Tugwood et al., 1992
; Varanasi et al., 1996
, 1998
) in rat and human hepatocytes. These experiments confirmed previously published reports (Hasmall et al., 2000
; Lambe et al., 1999
) that the human PPAR
does not activate a human PPRE derived from the ACOX promoter in either rat FAO or human HepG2 cells when treated with PPAR
agonists. Human PPAR
was not able to significantly activate the rat ACOX PPRE or the full-length ACOX promoter in human hepatocytes; an observation that was also evident for rat PPAR
and may reflect the nonresponsiveness of human hepatocytes as discussed in more detail later. In addition, human PPAR
did not activate the rat ACOX PPRE in rat FAO or primary hepatocytes. In contrast, others showed that human PPAR
was active on a rat ACOX promoter in murine cells (Hasmall et al., 2000
; Sher et al., 1993
). We also observed induction of the rat ACOX promoter in rat hepatocytes in the presence of human PPAR
, although this activity could not be discriminated from endogenous rat PPAR
. Taken together, overexpressed human PPAR
exerted some activity on the rat ACOX promoter; however, in our hands, this activity was lower than that of rat PPAR
at comparable mRNA expression levels. Lambe and colleagues (1999)
compared the identical human and rat PPRE sequences used in this study in transactivation assays using the mouse PPAR
. They showed that the human PPRE conferred no activity to mouse PPAR
whereas the rat PPRE was responsive to peroxisome proliferators (Lambe et al., 1999
). We confirmed that rat PPAR
did not activate through the human ACOX PPRE but distinctively induced the rat ACOX PPRE and the full-length rat ACOX promoter. The published results and our study showed that both human PPAR
and human PPRE sequence limit the activation of peroxisome proliferation related gene transactivation in hepatocytes.
Next we investigated whether the expression level of human PPAR could account for the observed lack of peroxisome proliferation related effects in human hepatocytes. Human PPAR
is expressed at low levels in liver compared to rodents (Braissant et al., 1996
; Lemberger et al., 1996
; Palmer et al., 1998
; Tugwood et al., 1996
) and we confirmed these different expression levels in the cell lines used for this study. Nevertheless, HepG2 and primary human hepatocytes had significant levels of PPAR
reaching up to 25% mRNA expression level compared to the rat FAO cells. In addition, overexpression of human PPAR
up to a level comparable to that observed for rat PPAR
in primary rat hepatocytes did not increase the induction of ACOX in human hepatocytes. Our observation was confirmed by other studies that showed that overexpression of human PPAR
in HepG2 cells did not increase the responsiveness to peroxisome proliferators with regard to ACOX mRNA expression and enzyme activity (Hsu et al., 2001
; Lawrence et al., 2001
). In contrast to these studies and our data are results obtained in hepatocytes of guinea pigs, a species that is not responsive to peroxisome proliferators (Macdonald et al., 1999
). In guinea pig hepatocytes, transfection of human or guinea pig PPAR
increased nafenopin-induced peroxisome proliferation related effects (Macdonald et al., 1999
). It is therefore likely that regulation of the peroxisomal marker enzyme palmitoyl-CoA oxidase may be differently regulated in guinea pig hepatocytes compared to human hepatocytes. Taken together, the lack of human PPAR
activity in human hepatocytes is unlikely to be due to the low level of human PPAR
expression. Palmer and colleagues (1998)
showed that splice variants of human PPAR
exist that lack activity and are dominant-negative (Gervois et al., 1999
). Our analysis of mRNA PPAR
expression was done with a TaqMan® probe that is located upstream of the spliced exon 6 of the inactive PPAR
variant (Palmer et al., 1998
). The observed amounts of human PPAR
mRNA in human hepatocytes correspond therefore to the total amount of wild-type and inactive human PPAR
variant. This inactive PPAR
splice variant could therefore contribute to the lack of peroxisome proliferation related effects observed in human hepatocytes.
We then scrutinized whether the above-described factors are sufficient to determine the species-specificity of peroxisome proliferation related effects. Hsu and colleagues showed that human hepatocytes, although refractory to peroxisome proliferation related effects, are susceptible to PPAR-mediated expression of CPT1A and HMGCS, genes that are involved in lipid metabolism in human liver (Hsu et al., 2001
). Here, we demonstrated that the primary human hepatocytes used maintained their PPAR
responsiveness with regard to CPT1A and HMGCS expression. In addition, Lawrence et al. showed that overexpressed human or murine PPAR
increased expression of HMGCS but not ACOX in HepG2 cells (Lawrence et al., 2001
). Consistent with this report, overexpression of rat PPAR
did not increase ACOX induction in human hepatocytes, which is likely due to the lack of responsiveness of the PPRE in the human ACOX promoter (Lambe et al., 1999
).
Intriguingly, we could not observe a distinct induction of rat or human ACOX PPRE or the full-length rat ACOX promoter in human hepatocytes when either human or rat PPAR was overexpressed to mRNA levels comparable to that observed in primary rat hepatocytes. Macdonald et al. showed that nafenopin induced activity of human and murine PPAR
on a rat ACOX PPRE in guinea pig hepatocytes (Macdonald et al., 1999
). However, others showed that Wy 14,643 induced weaklyabout 2-fold and less compared to the vehicle controlthe rat ACOX PPRE in HepG2 cells in the presence of overexpressed human PPAR
(Hsu et al., 2001
) consistent with our results. Hsu et al. demonstrated that a murine PPAR
mutant with an increased sensitivity for ligand-induced activation retained responsiveness to peroxisome proliferators in HepG2 cells (Hsu et al., 2001
). However, wild-type murine as well as human PPAR
displayed no distinct responsiveness to peroxisome proliferators on a rat ACOX PPRE in HepG2 cells (Palmer et al., 1998
) similar to our results. Since the rat PPAR
expression plasmid used in our study yielded similar transfection efficiencies and also comparably high mRNA expression levels in both rat and human hepatocytes and hepatoma cell lines, we conclude that human hepatocytes impede PPAR
-mediated induction of both rat and human ACOX reporter gene activity. However, depending on the properties of PPAR
, the target gene promoter or the potency of the PPAR
ligand, this unfavorable environment for peroxisome proliferation in human hepatocytes may be overcome.
In conclusion, our results confirmed that the differences in promoter sequences of PPAR target genes and the PPAR
contribute to the species-specificity of peroxisome proliferators in hepatocytes. However, these factors are not sufficient to determine the species-specificity of peroxisome proliferation, since human hepatocytes hampered a marked induction of peroxisome proliferation marker genes and PPAR
activity. It is therefore conceivable that hepatocytes may lack or overexpress co-regulators in a species-specific manner that might facilitate or inhibit PPAR
-mediated gene expression. Identification of these specific factors, which consequently may also be involved in the tumorigenic effects of PPAR
agonists in the rodent liver, would further enhance our understanding of the molecular mechanisms of the species-specificity of peroxisome proliferators.
![]() |
ACKNOWLEDGMENTS |
---|
![]() |
NOTES |
---|
2 To whom correspondence should be addressed. Fax: +49-6151-72 91 8517. E-mail: stefan.o.mueller{at}merck.de
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bieber, L. L., and Markwell, M. A. (1981). Peroxisomal and microsomal carnitine acetyltransferases. Methods Enzymol. 71, 351358.[Medline]
Bradford, N. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248253.[CrossRef][ISI][Medline]
Braissant, O., Foufelle, F., Scotto, C., Dauca, M., and Wahli, W. (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137, 354366.[Abstract]
Brandt, J. M., Djouadi, F., and Kelly, D. P. (1998). Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 273, 2378623792.
Cattley, R. C., DeLuca, J., Elcombe, C., Fenner-Crisp, P., Lake, B. G., Marsman, D. S., Pastoor, T. A., Popp, J. A., Robinson, D. E., and Schwetz, B. (1998). Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul. Toxicol. Pharmacol. 27, 4760.[CrossRef][ISI]
Clavey, V., Copin, C., Mariotte, M. C., Bauge, E., Chinetti, G., Fruchart, J., Fruchart, J. C., Dallongeville, J., and Staels, B. (1999). Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell. Physiol. Biochem. 9, 139149.[CrossRef][ISI][Medline]
Corton, J. C., Lapinskas, P. J., and Gonzalez, F. J. (2000). Central role of PPARalpha in the mechanism of action of hepatocarcinogenic peroxisome proliferators. Mutat. Res. 448, 139151.[ISI][Medline]
Duclos, S., Bride, J., Ramirez, L. C., and Bournot, P. (1997). Peroxisome proliferation and beta-oxidation in Fao and MH1C1 rat hepatoma cells, HepG2 human hepatoblastoma cells and cultured human hepatocytes: Effect of ciprofibrate. Eur. J. Cell Biol. 72, 314323.[ISI][Medline]
Gervois, P., Torra, I. P., Chinetti, G., Grotzinger, T., Dubois, G., Fruchart, J. C., Fruchart-Najib, J., Leitersdorf, E., and Staels, B. (1999). A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. Mol. Endocrinol. 13, 15351549.
Girnun, G. D., Domann, F. E., Moore, S. A., and Robbins, M. E. (2002). Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol. Endocrinol. 16, 27932801.
Goettlicher, M., Widmark, E., Li, Q., and Gustafsson, J. A. (1992). Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc. Natl. Acad. Sci. U.S.A. 89, 46534657.[Abstract]
Hasmall, S. C., James, N. H., Macdonald, N., Soames, A. R., and Roberts, R. A. (2000). Species differences in response to diethylhexylphthalate: Suppression of apoptosis, induction of DNA synthesis and peroxisome proliferator activated receptor alpha-mediated gene expression. Arch. Toxicol. 74, 8591.[CrossRef][ISI][Medline]
Hsu, M. H., Savas, U., Griffin, K. J., and Johnson, E. F. (2001). Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J. Biol. Chem. 276, 2795027958.
Hübl, P., and Breitschneider, R. (1964). Die Titanylsulfatmethode zur Bestimmung der Katalase in Blut, Serum und Harn. Hoppe-Seyler's Z. physiol. Chem. 335, 146155.[ISI][Medline]
Lambe, K. G., Woodyatt, N. J., Macdonald, N., Chevalier, S., and Roberts, R. A. (1999). Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol. Lett. 110, 119127.[CrossRef][ISI][Medline]
Lawrence, J. W., Li, Y., Chen, S., DeLuca, J. G., Berger, J. P., Umbenhauer, D. R., Moller, D. E., and Zhou, G. (2001). Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J. Biol. Chem. 276, 3152131527.
Lee, S. S., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., and Gonzalez, F. J. (1995). Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15, 30123022.[Abstract]
Lemberger, T., Braissant, O., Juge Aubry, C., Keller, H., Saladin, R., Staels, B., Auwerx, J., Burger, A. G., Meier, C. A., and Wahli, W. (1996). PPAR tissue distribution and interactions with other hormone-signaling pathways. Ann. N.Y. Acad. Sci. 804, 231251.[ISI][Medline]
Macdonald, N., Holden, P. R., and Roberts, R. A. (1999). Addition of peroxisome proliferator-activated receptor alpha to guinea pig hepatocytes confers increased responsiveness to peroxisome proliferators. Cancer Res. 59, 47764780.
Mukherjee, R., Jow, L., Noonan, D., and McDonnell, D. P. (1994). Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J. Steroid Biochem. Mol. Biol. 51, 157166.[CrossRef][ISI][Medline]
Palmer, C. N. A., Hsu, M.-H., Griffin, K. J., Raucy, J. L., and Johnson, E. F. (1998). Peroxisome proliferator activated receptor-alpha expression in human liver. Mol. Pharmacol. 53, 1422.
Perrone, C. E., Shao, L., and Williams, G. M. (1998). Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Tox. Appl. Pharmacol. 150, 277286.[CrossRef][ISI][Medline]
Reddy, J. K., and Chu, R. (1996). Peroxisome proliferator-induced pleiotropic responses: Pursuit of a phenomenon. Ann. N.Y. Acad. Sci. 804, 176201.[ISI][Medline]
Rodriguez, J., Gil-Gomez, G., Hegardt, F., and Haro, D. (1994). Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J. Biol. Chem. 269, 1876718772.
Seglen, P. O. (1973). Preparation of rat liver cells. 3. Enzymatic requirements for tissue dispersion. Exp. Cell Res. 82, 391398.[ISI][Medline]
Seglen, P. O. (1976). Preparation of isolated rat liver cells. Methods Cell Biol. 13, 2983.[Medline]
Sher, T., Yi, H. F., McBride, O. W., and Gonzalez, F. J. (1993). cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32, 55985604.[ISI][Medline]
Small, G. M., Burdett, K., and Connock, M. J. (1985). A sensitive spectrophotometric assay for peroxisomal acyl-CoA oxidase. Biochem. J. 227, 205210.[ISI][Medline]
Staels, B., Vu Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., and Auwerx, J. (1995). Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 95, 705712.[ISI][Medline]
Stangl, H., Kovacs, W., Bock, P., and Kremser, K. (1995). Differential induction of peroxisomal enzymes by hypolipidaemics in human (HepG2) and rat (MH1C1) hepatoma cell lines. Eur. J. Clin. Chem. Clin. Biochem. 33, 775783.[ISI][Medline]
Tugwood, J. D., Aldridge, T. C., Lambe, K. G., Macdonald, N., and Woodyatt, N. J. (1996). Peroxisome proliferator-activated receptors: Structures and function. Ann. N.Y. Acad. Sci. 804, 252265.[Abstract]
Tugwood, J. D., Issemann, I., Anderson, R. G., Bundell, K. R., McPheat, W. L., and Green, S. (1992). The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11, 433439.[Abstract]
Vanden Heuvel, J. (1999). Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Toxicol. Sci. 47, 18.[Abstract]
Varanasi, U., Chu, R., Huang, Q., Castellon, R., Yeldandi, A. V., and Reddy, J. K. (1996). Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene [published erratum appears in J. Biol. Chem. 1998 Nov 13;273(46):30842]. J. Biol. Chem. 271, 21472155.
Varanasi, U., Chu, R., Huang, Q., Castellon, R., Yeldandi, A. V., and Reddy, J. K. (1998). Additions and corrections to identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J. Biol. Chem. 273, 30842.
Willson, T. M. (2000). The PPARs: From orphan receptors to drug discovery. J. Med. Chem. 43, 527550.[CrossRef][ISI][Medline]